MX2021013132A - Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2). - Google Patents
Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2).Info
- Publication number
- MX2021013132A MX2021013132A MX2021013132A MX2021013132A MX2021013132A MX 2021013132 A MX2021013132 A MX 2021013132A MX 2021013132 A MX2021013132 A MX 2021013132A MX 2021013132 A MX2021013132 A MX 2021013132A MX 2021013132 A MX2021013132 A MX 2021013132A
- Authority
- MX
- Mexico
- Prior art keywords
- administration
- methods
- vmat2 inhibitors
- certain
- certain vmat2
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona un método para administrar un inhibidor del transportador 2 vesicular de monoaminas (VMAT2) a un paciente que lo necesita, en donde el paciente experimenta uno o más signos o síntomas clínicamente significativos de tipo parkinsoniano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962845599P | 2019-05-09 | 2019-05-09 | |
PCT/US2020/032188 WO2020227672A1 (en) | 2019-05-09 | 2020-05-08 | Methods for the administration of certain vmat2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013132A true MX2021013132A (es) | 2021-11-25 |
Family
ID=70919120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013132A MX2021013132A (es) | 2019-05-09 | 2020-05-08 | Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2). |
Country Status (15)
Country | Link |
---|---|
US (2) | US20200397779A1 (es) |
EP (1) | EP3965764A1 (es) |
JP (1) | JP2022531696A (es) |
KR (1) | KR20220007105A (es) |
CN (1) | CN114340624A (es) |
AU (1) | AU2020270145A1 (es) |
BR (1) | BR112021020709A2 (es) |
CA (1) | CA3136466A1 (es) |
EA (1) | EA202193012A1 (es) |
IL (1) | IL287902A (es) |
JO (1) | JOP20210274A1 (es) |
MA (1) | MA55893A (es) |
MX (1) | MX2021013132A (es) |
SG (1) | SG11202111465RA (es) |
WO (1) | WO2020227672A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230038601A (ko) | 2017-01-27 | 2023-03-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
EP3836926A4 (en) | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences, Inc. | METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS |
MX2023014827A (es) * | 2021-06-30 | 2024-01-15 | Neurocrine Biosciences Inc | Valbenazina para usarse en el tratamiento complementario de la esquizofrenia. |
IL310907A (en) | 2021-08-20 | 2024-04-01 | Neurocrine Biosciences Inc | Screening methods for VMAT2 inhibitors |
WO2023172849A1 (en) * | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US952A (en) | 1838-09-27 | I antoni bengini | ||
US10065A (en) | 1853-10-04 | Improvement in machines for topping cotton jn the field | ||
KR20160147044A (ko) * | 2014-05-06 | 2016-12-21 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 |
US20190015396A1 (en) * | 2015-06-23 | 2019-01-17 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for treating neurological diseases or disorders |
KR20230038601A (ko) * | 2017-01-27 | 2023-03-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
EP3836926A4 (en) * | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences, Inc. | METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS |
-
2020
- 2020-05-08 MX MX2021013132A patent/MX2021013132A/es unknown
- 2020-05-08 CA CA3136466A patent/CA3136466A1/en active Pending
- 2020-05-08 EP EP20729429.9A patent/EP3965764A1/en active Pending
- 2020-05-08 JP JP2021565932A patent/JP2022531696A/ja active Pending
- 2020-05-08 SG SG11202111465RA patent/SG11202111465RA/en unknown
- 2020-05-08 MA MA055893A patent/MA55893A/fr unknown
- 2020-05-08 KR KR1020217039903A patent/KR20220007105A/ko active Search and Examination
- 2020-05-08 CN CN202080034710.XA patent/CN114340624A/zh active Pending
- 2020-05-08 BR BR112021020709A patent/BR112021020709A2/pt unknown
- 2020-05-08 JO JOP/2021/0274A patent/JOP20210274A1/ar unknown
- 2020-05-08 EA EA202193012A patent/EA202193012A1/ru unknown
- 2020-05-08 AU AU2020270145A patent/AU2020270145A1/en active Pending
- 2020-05-08 WO PCT/US2020/032188 patent/WO2020227672A1/en unknown
- 2020-08-31 US US17/007,710 patent/US20200397779A1/en not_active Abandoned
-
2021
- 2021-10-21 US US17/506,883 patent/US20220040169A1/en not_active Abandoned
- 2021-11-08 IL IL287902A patent/IL287902A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN114340624A (zh) | 2022-04-12 |
TW202108138A (zh) | 2021-03-01 |
JP2022531696A (ja) | 2022-07-08 |
EP3965764A1 (en) | 2022-03-16 |
EA202193012A1 (ru) | 2022-03-02 |
JOP20210274A1 (ar) | 2023-01-30 |
AU2020270145A1 (en) | 2021-12-23 |
SG11202111465RA (en) | 2021-11-29 |
CA3136466A1 (en) | 2020-11-12 |
BR112021020709A2 (pt) | 2021-12-14 |
MA55893A (fr) | 2022-03-16 |
WO2020227672A1 (en) | 2020-11-12 |
US20200397779A1 (en) | 2020-12-24 |
IL287902A (en) | 2022-01-01 |
US20220040169A1 (en) | 2022-02-10 |
KR20220007105A (ko) | 2022-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210274A1 (ar) | طرق لإعطاء مثبط vmat2 معين | |
MX2022000559A (es) | Metodos para la administracion de ciertos inhibidores de vmat2 a pacientes con insuficiencia renal grave. | |
PH12021550302A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
PH12019501732A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
PH12020550237A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
NO20060416L (no) | Ny anvendelse I | |
CR20200553A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
EA200400966A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
RS52945B (en) | PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION | |
CR9694A (es) | Inhibidores de la transcriptasa reversa de vih | |
YU10101A (sh) | Prolekovi inhibitori proton pumpe | |
AR119158A1 (es) | Tratamientos de angioedema hereditario | |
CR20220199A (es) | Inhibidores del factor d del complemento para administración oral | |
AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
CL2022000889A1 (es) | Inhibidores del factor d del complemento para administración oral | |
MX2023014827A (es) | Valbenazina para usarse en el tratamiento complementario de la esquizofrenia. | |
MX2019005723A (es) | Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo. | |
WO2021239928A3 (en) | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling | |
EA202190252A1 (ru) | Способы введения определенных ингибиторов vmat2 | |
MX2022001044A (es) | Inhibidor de sglt2/dpp4 y su aplicacion. | |
JOP20210192A1 (ar) | إكتشاف و تصميم مركبات جديدة لعلاج مرض فايروس كورونا المستجد لسنة 2019 (كوفيد-19) | |
UA86082U (ru) | Способ лечения миопии | |
CO6390037A2 (es) | Combinación antitumoral que asocia ave8062 y docetaxel | |
UA49089U (ru) | Способ лечения острой сердечной недостаточности |